US - FTC Uses Its Consumer Protection Powers To Regulate Sellers Of GLP-1s. Legal News and Analysis - USA - Conventus Law ...

China is being viewed by the biotech and life sciences industry as a threat to US innovation. One pharma CEO thinks it may not be the worst thing to happen to the industry.

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...

Menopausal hormone treatment (MHT) might indirectly help with weight loss by improving sleep and redistributing abdominal fat ...

Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Shares in Europe dipped as concerns mounted that a U.S.-EU deal on tariffs won't be reached before the Aug. 1 deadline. European Union countries have hinted an appetite for a trade fight after Trump ...